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Introduction {#sec1}
============

Since the seminal report of DNA-encoded libraries (DELs) in 1992 ([@bib3]), academic laboratories, large pharmaceutical corporations, and biotechnology companies have all contributed to great advances in the technology, both in terms of library construction and selection methodology ([@bib4], [@bib15], [@bib16], [@bib22], [@bib35], [@bib40], [@bib41], [@bib57], [@bib60], [@bib56]). This progress has had a profound influence in the pharmaceutical industry by accelerating hit identification in drug discovery, sometimes for heretofore "un-druggable" targets. The popularity of DELs has also led to the development of new chemistries for DNA-compatible reactions, such as diversity-orientated synthesis (DOS) ([@bib6]), metal- or non-metal-mediated diverse synthesis ([@bib45], [@bib52], [@bib54], [@bib53]) and late-stage DNA annotation ([@bib28]), all in an effort to expand the chemical space coverage of DELs into more complex molecular structures. Currently, the diversity of DELs contains not only an unprecedented number of simple chemicals but also a collection of highly sophisticated stereo and spatial structures.

The ability to obtain functional molecules is arguably dependent upon the number and diversity of binding molecules in the initial DEL. DEL may be the only method that allows for simultaneous selection of many members of a library on the basis of affinity alone. Late-stage DNA encoding of natural products has been shown to yield selectable libraries with small numbers that are nevertheless rich in structural diversity ([@bib28]). Such encoding technology could be applied to other encoding molecules, such as peptide nucleic acids (PNAs) ([@bib7]). Traditional Chinese medicine (TCM) molecules are a family of natural products that are usually obtained from plant sources and have been used in medical therapies for more than 3,000 years. Although TCMs have been shown to be effective, the fact that their targets are generally unknown poses a significant challenge for pharmaceutical companies wishing to further improve their efficacy. Nevertheless, over the course of natural evolution these molecules have evolved highly diverse and complicated chemical scaffolds. In an effort to generate a small molecule with insulin-like activity we selected for study 160 TCMs, solely on their availability in pure form. These were encoded with DNA and then incorporated into a relatively small DEL.

Owing to its essential role in glucose homeostasis, insulin signaling has been extensively studied from the viewpoints of both the nature of receptor/ligand structures ([@bib10], [@bib17], [@bib30], [@bib42], [@bib46]) and the activation mechanisms ([@bib8], [@bib21], [@bib29]). The insulin receptor (IR) belongs to a large family of transmembrane tyrosine kinase receptors that is activated by insulin, insulin-like growth factor 1 (IGF-I), and insulin-like growth factor 2 (IGF-II) ([@bib1]). These endogenous ligands display a negative cooperative kinetics when binding to and activating the IR ([@bib8]). Insulin has been shown to activate the IR through stabilizing the active conformation of the covalent IR dimer, which is pre-formed in a symmetrical and anti-parallel arrangement in the cell membrane, by cross-linking the two binding sites (site 1 and site 2) on the ectodomain of each subunit ([@bib2], [@bib9], [@bib12], [@bib18], [@bib20], [@bib24], [@bib26], [@bib34], [@bib47], [@bib49], [@bib51]). In spite of our detailed understanding of the mechanism by which the IR is activated, attempts to identify orally available small molecule insulin mimetic have met with little success ([@bib13], [@bib39], [@bib44], [@bib50]). A key limiting factor, in addition to issues of toxic side effects and solubility, has been the lack of structural diversity among candidate molecules.

Herein we used a structurally diverse DEL containing 160 TCMs to select a small molecule that binds to and activates the IR. More importantly, we showed that this activation results in insulin-like activity in a cell-based system. In a remarkable coincidence, the selected molecule is a TCM that has been shown to lower blood glucose in murine diabetes models ([@bib5], [@bib36], [@bib37]). These findings should encourage attempts to develop a small molecule replacement for insulin. Such a molecule would offer significant advantages in diabetes therapy, as it would be orally available and have an easily standardized dosage.

Results and Discussion {#sec2}
======================

Late-Stage Modification Toolbox for DNA Encoding of Natural Products {#sec2.1}
--------------------------------------------------------------------

In our previous work, we described a volatile bifunctional linker that could quantitatively annotate a complex organic molecule at any particular site with a DNA barcode sequence ([@bib28]). However, for chemicals lacking functional groups such as amines, hydroxyl groups, and carboxylic acids, this volatile linker alone was not sufficient owing to poor labeling efficiency. To increase the site diversity for the labeling of natural products with DNA barcodes, we expanded the toolbox by developing several new bifunctional linkers with complementary reactivity. As shown in [Figure 1](#fig1){ref-type="fig"}, these included carbine precursors (**L1** and **L2**), a radical precursor (**L3**), and a nitrene precursor (**L4**). These linkers can be used to add azide or alkyne functional groups on to natural products, so that the copper-catalyzed azide-alkyne cycloadditions (CuAAC) ([@bib23]) can proceed under DNA-compatible reaction conditions. Thus, these chemistries are suitable for efficient late-stage DNA annotation of diverse natural products. The diazoacetate containing linker **L2** introduces alkynes through C-H or C-X (X = OH, or NH~2~) insertion ([@bib19], [@bib38]), whereas the difluoroalkyl-sulfinate bifunctional linker **L3** has been shown to directly functionalize the C-H of (hetero)arenes ([@bib59]). Using sulfonamide as a nitrene precursor ([@bib27]), **L4** was expected to undergo intermolecular C(sp^3^)-H amination reactions to add an alkyne group on to natural products. As shown in [Scheme 1](#sch1){ref-type="fig"}, the synthesis of **L4** was commenced from Sonogashira cross-coupling of 4-iodophenol **(L4-a)** and ethynyltrimethylsilane (**L4-b)** to afford **L4-c**, which was subsequently reacted with sulfamoyl chloride in the presence of *N*,*N*-diisopropylethylamine to give the desired **L4** linker. Next, Rutaecarpine (**Rut-0)** was functionalized by **L4** using bis\[rhodium (a,a,a′,a\'-tetramethyl-1,3-benzene dipropionate)\] \[Rh~2~(esp)~2~\] as the catalyst ([@bib11]) and PhI(OAc)~2~ as the oxidant to afford the desired amination product **Rut-1** in 23% yield. Using this expanded toolbox, a total of 160 TCMs were annotated and included in the *n*DEL library ([Table S1](#mmc2){ref-type="supplementary-material"}).Figure 1Late-Stage Modification Toolbox to Annotate Natural Products with DNAChemical structures highlighted in the frame are the representative DNA-encoded natural products in *n*DEL.Scheme 1Late-Stage Modification of RutaecarpineReagents and conditions: (a) Pd(Ph~3~P)~2~Cl~2~, CuI, Et~3~N, DMF, 80°C, 72%; (b) DIPEA, DCM, 63%; (c) Rh~2~(esp)~2~, PhI(OAc)~2~, CH~3~CN, 23%.

Affinity-Based Selection of *n*DEL Members that Bind to the Insulin Receptor {#sec2.2}
----------------------------------------------------------------------------

The *n*DEL screening was carried out using the purified recombinant extracellular domain of the human insulin receptor (ECD-*h*IR), which was immobilized on either cobalt beads by the C-terminal polyhistidine tag or streptavidin beads through biotin modification. The bound *n*DEL molecules were collected using conventional heat denaturation. The screening fingerprint of the *n*DEL was plotted as enrichment fold versus normalized sequencing counts as shown in [Figure 2](#fig2){ref-type="fig"}. Compared with the negative control, the enrichment pattern was similar in both cobalt bead-based screening and streptavidin bead-based screening, indicative of strong non-specific interactions. The maximum enrichment was also similar, with a 54-fold enrichment using empty cobalt beads versus a 66-fold enrichment with his-tag-insulin receptor-attached cobalt beads, and a 185-fold enrichment using empty streptavidin beads versus a 121-fold enrichment with biotinylated insulin receptor on streptavidin beads. Thus, a more stringent screening strategy was necessary.Figure 2Fingerprint Patterns for *n*DEL Screening of the Insulin ReceptorFingerprints for *n*DEL selection against streptavidin-beads (A), biotinylated insulin receptor attached to streptavidin-beads (B), cobalt-based beads (C), and his-tag insulin receptor attached to cobalt-based beads (D). Red dashed lines are the cut-offs for hits selection.

Insulin Elution of *n*DEL Members Bound to the Insulin Receptor {#sec2.3}
---------------------------------------------------------------

As demonstrated above, it is likely that heat denaturation will liberate any compound whose binding depends on a particular secondary or tertiary structure. Since insulin binds to and activates the IR, we reasoned that elution with insulin should liberate compounds with more functional binding to the IR. The IR is a complex dimeric protein consisting of two identical extracellular α subunits each containing two sites that bind to insulin with different affinity ([@bib14], [@bib32]). The binding of the intrinsic ligand, insulin, follows negative cooperative kinetics ([@bib8]) suggesting an optimal concentration of insulin that preferentially binds to the active form of the IR. Using the streptavidin beads, the optimal activation concentration of insulin (100 nM) was used to competitively elute bound *n*DEL members. As expected, insulin elution generated a significantly enriched fingerprint pattern relative to the negative control ([Figure 3](#fig3){ref-type="fig"}). More interestingly, a TCM, Rutaecarpine, was shown to be enriched over 50-fold when eluted with insulin, as compared with less than 5-fold enrichment when eluted with heat denaturation ([Table 1](#tbl1){ref-type="table"}), indicating possible specific and functional binding to the IR.Figure 3Fingerprint Patterns of *n*DEL Screening of the Insulin Receptor Using Insulin as the Competitive EluentFingerprints for *n*DEL selection using 100 nM insulin elution against streptavidin-beads (A), biotinylated insulin receptor attached to streptavidin-beads (B). Red dashed lines are the cut-offs for hits selection. Red dots represent the DNA-conjugated TCM hit, Rutaecarpine.Table 1Enrichment of DNA-encoded Rutaecarpine under Different Selection Conditions.Heat Denaturation ElutionInsulin ElutionCobalt-Based BeadsStreptavidin BeadsStreptavidin BeadsControl2.951.422.14Sample4.472.3351.5

Rutaecarpine Is an Analog of Metformin {#sec2.4}
--------------------------------------

Metformin ( CSD-JAMRIY01) ([@bib63]) , an oral diabetes medicine, showed striking structural similarity to Rutaecarpine (CSD-OGAXEC)[@bib61] , in that the arrangement of the five nitrogen hetero atoms of the bis-guanidine appears to be the same in both molecules ([Figure 4](#fig4){ref-type="fig"}A).Figure 4Rutaecarpine and Metformin Directly Bind to the Insulin Receptor(A) Overlay of crystal structure of Rutaecarpine (green, CSD-OGAXEC) and Metformin (pink, CSD-JAMRIY01), in which oxygen (red), nitrogen (blue), and hydrogen (white) atoms are labeled with different colors. X-ray structures are obtained from the Cambridge Crystallographic Data Center (CCDC) ([@bib62]); (B--E) Rutaecarpine and Metformin bind to the insulin receptor extracellular domain as quantified by surface plasmon resonance measurements (B and D). Graphs of equilibrium response unit versus compound concentrations are plotted (C and E). The estimated K~D~ is 14 μM for Rutaecarpine and 84 μM for Metformin.

Both Rutaecarpine and Metformin Bind to the Insulin Receptor {#sec2.5}
------------------------------------------------------------

In order to understand the mode of action of Rutaecarpine, we tested if Rutaecarpine directly targets insulin receptor *in vitro* using surface plasmon resonance technology. Rutaecarpine exhibited moderate binding affinity to the IR extracellular domain (amino acids 1--956) with an estimated dissociation constant (K~D~) of 14 μM, and indeed, Metformin also bound to the insulin receptor but with a weaker K~D~ value of 84 μM as shown in [Figures 4](#fig4){ref-type="fig"}B--4E.

To determine if the binding of Rutaecarpine triggers conformation change in the IR, we carried out a partial proteolytic digestion of the IR. The human recombinant insulin receptor extracellular domain (ECD-*h*IR) was incubated with 5% DMSO, or 50 μM Rutaecarpine in 5% DMSO, followed by limited trypsin digestion. As shown in [Figure S1](#mmc1){ref-type="supplementary-material"}, SDS-PAGE analysis showed that the pattern of trypsin digestion was altered in the presence of Rutaecarpine. A digestion ladder appeared below the main ECD-*h*IR band, indicating that Rutaecarpine bound to the ECD domain of the IR, changed its confirmation, and facilitated the enzyme digestion. In contrast, Rutaecarpine did not affect the trypsin cleavage pattern of an irrelevant protein, BSA, thus ruling out the possibility that Rutaecarpine is a protease enhancer.

Rutaecarpine and Metformin Activated Autophosphorylation of the Insulin Receptor on Cells {#sec2.6}
-----------------------------------------------------------------------------------------

The IR exists on the cell membrane as a homodimer consisting of two extracellular α subunits that bind insulin, as well as two transmembrane β subunits that have intracellular tyrosine kinase activity ([@bib14], [@bib32]). When insulin binds to the α subunit of the receptor, the β subunit tyrosine kinase is activated, resulting in autophosphorylation of β subunit tyrosine residues. This autophosphorylation is considered a hallmark of IR activation and, in turn, activates the downstream signaling. CHO cells expressing the human IR were treated with 10 μM Rutaecarpine and Metformin. Five percent DMSO and 100 nM insulin were included as negative and positive controls, respectively. Rutaecarpine and Metformin stimulated significant autophosphorylation of the human insulin receptor as expected ([Figure 5](#fig5){ref-type="fig"}). It was noted that Metformin also showed sensitization effect of insulin on the activation of IR, consistent with the literature reports ([@bib31], [@bib43], [@bib25]).Figure 5Effects of Rutaecarpine on the Autophosphorylation of the Insulin Receptor.Comparison of autophosphorylation of the insulin receptor in CHO-*h*IR cells, in which10 μM Rutaecarpine (Ru), 10 μM Metformin (Met), 100 nM Insulin, and 5% DMSO dissolved in media (DMSO) were incubated with the CHO-*h*IR cells. The y axis represents the absorbance at 450 nm developed by the specific antibody targeting phosphorylated insulin receptor. The error bar was determined from the data of three independent experiments. Statistical analysis between two groups was performed using unpaired Student\'s t test. (∗p \< 0.05, n = 3)

Analysis revealed this compound to be Rutaecarpine, a TCM obtained from the plant *Evodia rutaecarpa*, also called "吴茱萸 (Wu Zhu Yu)" ([@bib33]). "吴茱萸" is a medical herb described in "Divine Farmer\'s Classic of Materia Medica," the oldest medical book in China during the period of Qin and Han dynasties more than 2,000 years ago. The herb is slightly toxic and has been used to treat respiratory infections, inflammation, pain, hypertension, and diarrhea. It is one of the two active ingredients in the famous medical formulation "Zuojin Pills" developed by Dr. Zhu, Danxi (朱丹溪) during the Yuan dynasty, more than 800 years ago. To this day, in China, this formulation is still being used to treat gastritis and hypertension. Modern research on Rutaecarpine of "Wu Zhu Yu" in animals showed strong glucose regulation and insulin sensitization effects ([@bib36], [@bib37], [@bib55], [@bib48]). In spite of its long history, Rutaecarpine\'s mechanism of action remains unknown. Our structural studies have shown Rutaecarpine to be an analog of the important diabetes drug Metformin, in that all the N hetero atoms are in a similar position relative to each other and "locked down" by rings. Until now the mechanism by which Metformin functions was unknown. Most mechanistic concepts center around the role of Metformin in the activation of AMP-activated protein kinase (AMPK) ([@bib58]). Our findings indicate that Metformin may bind to and activate the IR, which should allow a better understanding of its mechanism of action and, in turn, could lead to synthesis of better analogs of this important drug. For instance, the binding of Metformin to the IR could be responsible for the known sensitization effect of Metformin on the insulin signaling both in cells and in human ([@bib31], [@bib43], [@bib25]).

One may ask why selection from a small, albeit diverse, DEL should have yielded a molecule with such profound metabolic effects. Although it was not known that any of the DEL components, including Rutaecarpine, would bind the IR, using the IR as the target for binding could be expected to bias the selection process toward molecules having metabolic effects. In this case binding of Rutaecarpine to the IR was highly specific, as Rutaecarpine was not selected when other proteins were used as the target. The IR itself is a highly evolved protein that is carefully integrated into the plasma membrane and as such may not tolerate perturbation without becoming activated. The binding of hydrophobic organic compounds could easily be a major perturbation. Perhaps membrane receptors that are poised to signal by changing their conformation may be especially susceptible to activation by binding hydrophobic organic molecules. Thus, it is possible that the only requirement to achieve results similar to those reported here is to choose the right receptor target for study and to pair it with its natural ligand for elution (i.e., in this paper *n*DEL members binding to the IR were eluted with insulin). This insight, together with the concept that one needs initially select only for binding, should guide further investigations.

Conclusion {#sec2.7}
----------

In summary, we developed a tool box of complementary bifunctional linkers that contain carbine precursors, radical precursor, nitrene precursor, and azide or alkyne functional groups to expand the chemical space of DNA-encoded library. By using the natural ligand, insulin, for competitive elution, we discovered a polycyclic nature product named Rutaecarpine, which is capable of both binding to and activating the IR. The experiments reported here rely on the concept that one of the main strengths of DELs is that they allow for selection based only on binding, with the assumption that once such molecules are found, some of them will be functional. In this case, selection using a relatively small but highly diverse DEL will yield a compound capable of both binding to and activating the target.

Limitations of the Study {#sec2.8}
------------------------

This is a highly diverse and small natural product-enriched DNA-encode library (nDEL) that designed for the concept proof; the number of natural products in this nDEL should keep increasing to cover larger chemical space.
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